This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

No Big Ripple for Merck Vioxx Verdict

Updated from 4:30 p.m. EDT

Merck (MRK - Get Report) confirmed Wednesday that it won an appeal in a liability case related to Vioxx.

A Texas appeals court overturned a verdict that had awarded $7.75 million to the widow of a 71-year-old heart attack victim. Leonel Garza had died after taking Vioxx for a month.

The drug was pulled from the market in 2004 after research showed it increased the risk of heart attack and stroke.

The jury's original verdict on April 21, 2006, included $7 million in compensatory damages and $25 million in punitive damages for a total of $32 million against Merck, the company said in a statement. In December of that year, the punitive award was reduced to $750,000 in compliance with Texas statutory caps.

Fordham Law professor Ben Zipursky, who specializes in product liability law in the pharmaceutical industry, said it's important to realize this was a very weak case. Aside from the risk factors that Garza had prior to taking Vioxx, one of the jurors failed to disclose that he had borrowed money from the widow in the suit, said Zipursky. "It's clear that this case, for any number of reasons, stands very little chance of ever coming back in favor of the plaintiff."

But, don't expect this case to affect anything aside from a few other cases in Texas, says the law professor. Overwhelmingly, the settlement agreement will handle these cases and there's no reason to believe it won't keep moving forward, he says.
1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
MRK $57.67 0.00%
AAPL $126.44 0.00%
FB $87.28 0.00%
GOOG $523.40 0.00%
TSLA $280.02 0.00%

Markets

DOW 17,730.11 -27.80 -0.16%
S&P 500 2,076.78 -0.64 -0.03%
NASDAQ 5,009.2140 -3.9090 -0.08%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs